Cultivation

Last reviewed 5 October 2026

What it is

When a laboratory studies a plant, a fungus or an animal secretion, the organism is part of the instrument. What it contains depends on its genes, on what it grew on and in, on how old it was when collected, and on what happened afterward. A study that does not record those things cannot be repeated, and two studies of "the same" organism may be measuring different material. Cultivation, as a research discipline, is the study of those steps and of how much each one moves the chemistry.

A strain is a named line of one species, kept by transferring cultures from one generation to the next. A fruit body is the part of a fungus that people recognize as a mushroom, and mycelium is the web of fine threads that makes it. A sclerotium is a hardened mass of mycelium that some species form, sold in some countries as "magic truffles". A flush is one wave of fruit bodies from the same batch. Each of these terms appears in the studies below as something that was measured, never as something to do.

The discipline reaches beyond mushrooms, to peyote (a cactus whose generation length is 50 years in the IUCN Red List assessment [14]), iboga [17] and the Sonoran Desert toad [23]. In each case the issue matches the one fungi raise: where does the material come from, and can the source be studied without being depleted?

What is known

Most of the controlled evidence concerns Psilocybe mushrooms, so this section begins there and then turns to plants and animals. The studies report concentrations in dried material and genetic comparisons and cannot say anything about effects in healthy adults.

Species and strains differ even when everything else is held the same

A 2026 study from a single laboratory grew six Psilocybe species indoors, confirmed each by microscopy and by DNA testing at independent laboratories, on one fruit body per species, and measured psilocybin by high-performance thin-layer chromatography, which the authors describe as semi-quantitative. Species means for psilocybin ran from 0.84 percent of dry weight in one species to 1.46 percent in another, with 5 to 25 samples per species. All authors were employed by the company that grew the material, and the company states a financial interest in developing cultivars [1].

In a second 2026 study, fourteen strains of Psilocybe cubensis grown under a single protocol and analyzed with one method ranged from 2.62 to 20.65 milligrams of total tryptamines per gram of dried material, a spread of more than sevenfold. Two limits matter. Each strain was grown in one container only, so differences between strains cannot be separated from differences between containers and batches, and the strain figure came from a single ground powder per strain, measured in technical replicates, and not from independent growings. The ranking also shifts with the sample: one strain read 13.53 milligrams of psilocybin per gram in the first table and 6.43 as the mean of its individual fruit bodies in the second. Strain identity rested on appearance, the supplier's label and public descriptions, DNA sequencing confirmed only that all 14 belong to one species, and no comprehensive genetic reference exists for these strains [2].

Fruit bodies from one strain differ from each other

In the 14-strain study, five individual fruit bodies from each of six strains, grown in the same container and harvested together at the same stage, differed in psilocybin with a coefficient of variation (spread relative to the average) of 12.81 to 23.39 percent. Sampling a single mushroom, the authors conclude, can mislead [2].

Another species shows the same pattern, with a limit. In a 2024 study of Psilocybe zapotecorum, all the material came from one clone grown from wild spores. Seven samples of whole fruit bodies held between 10.6 and 25.7 milligrams of psilocybin per gram, a 2.4-fold spread around a mean of 17.9, so this is spread between samples of one clone and not between strains. The paper does not say how many fruit bodies stand behind each sample. In separate sets of seven samples, caps averaged 25.5 and stems 15.6 milligrams per gram, a significant difference [3]. According to its abstract, a 2021 study of P. cubensis saw the same direction, with stems holding about half the tryptamines of caps, but the difference was not statistically significant because individual fruit bodies varied so much [4].

The two zapotecorum measurements, 1.46 percent by thin-layer chromatography in 25 samples [1] and 1.79 percent by liquid chromatography in seven samples [3], differ in strains, methods and sample sizes, which shows why a number without its method is hard to use.

Maturity, tissue and what happens after harvest

The six-species study also compared fruit bodies taken at four stages from a single growing bag. In four of the species, psilocybin and psilocin (the compound psilocybin converts into) both fell as the mushrooms matured, which the authors call preliminary and based on limited data. A qualitative comparison of chromatography fingerprints across three flushes in one species looked similar, with no figures reported [1].

Handling mattered a great deal. When fresh mushrooms were stored frozen for a day before freeze-drying, psilocybin in one species fell from 1.29 to 0.08 percent and in another from 1.16 to 0.27 percent, while psilocin rose from 0.04 to 0.08 percent in the first and from 0.31 to 0.77 in the second, the latter above the calibration range of the method. In the first species the rise in psilocin is far smaller than the fall in psilocybin [1]. A separate stability study, read as an abstract only, reported a similar ordering, with frozen fresh mushrooms losing the most tryptamines and dried material kept in the dark the least, and it reported no tryptamines in spores [4]. Mycelium held much less psilocybin than fruit bodies in two other studies. One measured 0.041 milligrams per gram in mycelium against 9.913 in fruit bodies across several species, and all of its authors work for the company that funded it [36]. The other found 6.3 to 6.4 in the mycelium of one P. cubensis cultivar, against 10.5 to 20 in its caps [34]. A systematic review of 25 extraction studies found that method and species both changed measured yields, by more than 30 percent between methods for the same species, and that reproducibility received the most low or unclear quality ratings [12].

A reported potency figure is therefore a property of the organism, harvest stage, tissue, storage and laboratory method all at once. A 2026 narrative review put the reported psilocybin range at 0.01 to 3.04 percent of dry weight and said the variation likely reflects genetics, substrate, growing conditions, origin and handling, none controlled or reported systematically [13].

What growing conditions change: one controlled test

For the question that gives the discipline its name, the controlled evidence is thin. In the searches run for this page, a single study varied cultivation conditions one at a time in genetically authenticated P. cubensis and measured tryptamines, testing two common commercial practices. Only its abstract could be read. According to the abstract, one treatment raised biological efficiency, a standard measure of yield, roughly fourfold and delayed fruiting by about two days, and total tryptamine content was 0.85 percent in one treated group and 0.95 percent in the other [6]. The abstract's yield figures for the two treatments cannot be reconciled with each other, and the closed-access full text could not be obtained, so whether yield and tryptamine content trade against each other is not verified here. Several authors list a company, Future Wellness (formerly Field Trip Natural Products), as their affiliation.

A narrative review published in 2025, which followed no stated search protocol, reached a matching verdict. It found knowledge of how growing conditions affect psilocybin production to be very limited, noted that much strain-level information comes from community reports, and cites older studies of nutrients, humidity and light that were not read at the source for this page and are not used here [8].

Licensed cultivation and what it has produced

In Jamaica, researchers grew P. cubensis in what they describe as a legally sanctioned laboratory. Mean psilocybin plus psilocin content was 1.14 percent by weight (standard deviation 0.17), batches differed enough that the authors recommend testing every batch, the material met their limits for contaminants, and capsules kept their tryptamine content for 11 months [7]. A 2026 review describes this work as showing good consistency under controlled growing, with outlying batches from 0.66 to 1.54 percent [13]. Several authors list Future Wellness as their affiliation. Jamaican law on this activity is not verified, since the statute was not read.

Licensing frameworks treat cultivation as a regulated activity in several places, and they differ. In Oregon, the Oregon Health Authority describes a manufacturer license as covering indoor cultivation or processing of natural psilocybin products. This is Oregon state law, from an official page last read on 4 October 2026 [29]. The statute is said to define manufacture to include cultivation and to bar a licensed manufacturer from producing products outdoors, but both points were read only on a third-party mirror and are not verified against the legislature's own text [30]. In Colorado, under state law, the Department of Revenue's Natural Medicine Division began accepting license applications on 31 December 2024 and, as of 25 September 2026, listed 14 approved standard cultivation licenses. Its FAQ also says that a person 21 or older may grow psilocybin mushrooms for personal use in a locked space of 12 by 12 feet, secured against anyone under 21. That is the division's own description under state law, and the statute behind it was not read [31]. The Dutch Opium Act, in the official version in force from 17 September 2026 (read 2 and 4 October 2026), places mushrooms that naturally contain psilocin or psilocybin on List II, with growing of List II substances prohibited by Article 3, and the isolated compounds on List I. A search of the Act for sclerotia and truffles, in Dutch, found no mention, and Dutch practice is not verified [32]. The company behind the six-species study states that Health Canada licenses it to grow psilocybin-containing species [1], which is its own statement and is not verified with Health Canada.

All of these sit beside federal law in the United States. The federal Schedule I list in 21 CFR 1308.11 (eCFR up to date as of 1 October 2026, accessed 4 October 2026) includes psilocybin, psilocyn, mescaline, peyote, ibogaine and 5-MeO-DMT [33]. It names the compounds and does not mention mushrooms or the genus Psilocybe, and how it applies to the fungi was not examined for this page. Peyote also has an international layer: the CITES checklist places Lophophora williamsii in Appendix II, with Mexico and the United States as range states, as read on 4 October 2026 [38].

Where the commercial strains came from

One study compared 86 genomes of commercial P. cubensis cultivars with 38 isolates from Australia. The Australian population has recovered its genetic diversity after being introduced, while the commercial cultivars show low diversity and the marks of self-fertilization and clonal propagation (copying a strain without mixing genes), and most were founded from related populations. The alleles (alternative versions of a gene) of the psilocybin gene cluster were identical across most cultivars [9].

The closest known wild relative of P. cubensis, Psilocybe ochraceocentrata from sub-Saharan Africa, was described in 2026. The two species last shared an ancestor about 1.5 million years ago, with a 95 percent credible range of roughly 710,000 to 2.55 million years. Only the 2024 preprint of the study could be read in full, and it says the dating rests on a root-age calibration borrowed from earlier work by the same group [10]. The prevailing account, that P. cubensis reached the Americas with introduced cattle around 1500, is reported as background in the published abstract, and the preprint says it had never been tested. Both species live on the dung of large herbivores, which suggests the habit is older than the cattle. In the preprint, habitat models built from P. cubensis records suggest a suitable range across Africa, Asia and the Americas over the last 3 million years. Its authors say they can neither confirm nor rule out an American origin for P. cubensis, that earlier African records were probably misidentified, and that no verified African specimen of the species is known [10].

Since the gene cluster is nearly the same in most commercial cultivars and yet total tryptamines differ more than sevenfold under one protocol, the difference may lie in how strongly the genes are switched on, how many copies there are, an interaction with growing conditions or plain fruit-body-to-fruit-body noise, and not in the gene sequences. A 2024 study of a related species, Psilocybe mexicana, found that genes that make and use tryptophan were switched on and off by large factors between culture medium and fruit bodies, but it compared life stages and media in one strain and did not identify the regulating factor, so it shows that regulation can vary and not that it explains the strain gap [37]. This is a reading across four papers, and none reports it as a result. The cultivars in the genomic study are also not guaranteed to be the strains in the chemistry study.

Identity and uncontrolled material

Appearance and names are weak guides to identity. A 2016 forensic study used DNA to identify the fungus in seized grow kits, and mushrooms later grown from them held 1.02 to 7.60 milligrams of psilocybin per gram and 0.415 to 8.36 of psilocin [11]. DNA barcoding of 94 museum specimens found that about 13 percent of those labeled Psilocybe belonged to other genera, few museum specimens of P. cubensis held measurable psilocybin or psilocin, and the authors had no record of how each had been preserved [34]. A 2025 study of 42 strains grown by one company found a mismatch between morphological label and DNA identification in at least 12 of the 42, among them strains sold as P. natalensis that proved to be P. cubensis, and the chemical grouping matched the DNA identification better than the label [35]. The Africa preprint adds that a commercial strain sold as P. natalensis does not match that species' type specimen and that four of its five public sequences group with the newly described African species [10]. A 2022 survey of 226 fruit bodies from 82 collections in seven genera, a mix of the authors' field collections, donations from the public and dried museum specimens, found tryptamine concentrations "extremely variable", including differences between fruit bodies that seemed to share a mycelium, and three taxa held none at all [5]. Some samples waited up to nine years before analysis and the donated ones were dried by volunteers, so part of the variation may reflect time and drying as well as biology. In the same survey, nine P. cubensis fruit bodies from four collections held psilocybin from 0.651 to 3.509 milligrams per gram and psilocin from 0.208 to 5.344. Two secondary sources present the psilocin range as a psilocybin range [8] [13], so a spread quoted from them should be checked against the original. Uncontrolled material therefore cannot be assumed to contain what its label says.

Plants and animals: cultivation as an alternative to wild collection

For fungi, the argument for cultivation is reproducibility. For slow-growing plants and for an animal, it is also conservation.

Peyote (Lophophora williamsii) is listed as Vulnerable (criteria A4acd) in a Red List assessment dated 19 November 2009 and published in 2017, annotated by the Red List itself as needing updating, with a decreasing trend and livestock ranching and plant gathering as threats [14]. In a survey of wild populations in Texas, densities were uneven at the scales examined. Only 14 of 121 survey strips (12 percent) held any plants, all six sites were chosen because the species was already known to grow there, and the authors could not tell whether climate, terrain or harvesting explained the differences between regions [21]. A 2018 paper on in vitro germination gave protection of wild populations as its purpose [22].

Two research groups worked out the enzymes that make mescaline in peyote within a year of each other [18] [19], and the second reports that several problems still block complete production outside the cactus [19]. A forensic laboratory, citing peyote specimens that contain no mescaline, compared gene expression between mescaline-positive and mescaline-negative groups [20], which matches the fungal picture that the species name alone does not tell a researcher what a plant holds.

Iboga (Tabernanthe iboga) is rated Least Concern (assessed 12 June 2018, published 2019), with a stable population [15]. A 2018 study of ibogaine biosynthesis says that commercial ibogaine comes from plants, that therapeutic use is contributing to overharvesting, and that conservation is a primary concern of the Bwiti community, but it gives no harvest figures [17]. The statements are compatible, since a global category averages over the whole range, but nothing read for this page settles how heavy the local pressure is.

The Sonoran Desert toad (Incilius alvarius) is also rated Least Concern (assessed 16 October 2019, published 2022), with a stable population [16]. A 2025 field study near Tucson, Arizona, analyzed the secretions of 26 toads by mass spectrometry, which can show that a compound is present but not how much, and found 5-MeO-DMT in every one but not in nine individuals of two neighboring toad species with a similar generalist diet, so diet is unlikely to be the source. The origin of 5-MeO-DMT in this species is unknown, with an enzyme made by the toad, a microbial partner, and a plant or fungal source as open possibilities [23]. In a pilot study, 5-MeO-DMT was detected in the medium of a cell line grown from gland biopsies of two toads, with no measured yield, and the authors say that production from scratch by the cells remains to be confirmed. The first author holds shares in a company developing the technology. The authors describe the species as under severe ecological pressure, although the source they cite concerns amphibian declines in general and gives no data on this species, and the cells came from living toads [24]. No source read here gives a population count.

Production in other organisms, for comparison

Engineered yeast was reported in 2020 to make 627 milligrams of psilocybin per liter in fed-batch fermentation (a culture fed nutrients in stages), alongside a similar amount of psilocin, over about 214 hours in triplicate. Two authors are inventors on a related patent application, and the authors call the buildup of psilocin a key challenge [25]. A 2026 report described an engineered bacterium reaching 1.88 grams of psilocybin per liter in bioreactors [26]. These systems make a defined molecule and a few intermediates, some identified only tentatively because no authentic standards were available [25]. That a defined medium would make batches easier to compare is this page's reading, and neither paper makes it. They do not reproduce the full mixture of compounds an intact organism makes. A 2026 narrative review concluded that preliminary preclinical evidence points to possible interactions between the compounds, that human validation is lacking, and that whole biomass ranked lowest among preparation types for precision of content, while citing controlled cultivation as able to give good consistency [13]. Cultivation research can only describe what the material is.

Sustainability is not automatic

Cultivation carries costs of its own. A 2026 review describes waste materials and non-arable indoor space as an advantage of growing psilocybin mushrooms, and lists energy-intensive sterilization and climate control, spore release into indoor air and possible effects of spores on wild genetic diversity as costs. It also reports, from ethnographic work, that wild mushrooms have become harder to find for one community in Oaxaca, Mexico, because of changing rainfall and deforestation [13]. These points come from a narrative review with no formal search protocol, not from measurements of a cultivation facility.

Where the evidence is weak, and what came back empty

Sample sizes are small, from 5 to 25 per species and seven per measurement in the zapotecorum work, which used a single clone. Most results come from single laboratories, and in the 14-strain study each strain was grown once. Several come from companies with a commercial interest in cultivars or products [1] [6] [7] [36], and all five authors of one review are also authors of the 14-strain paper [2] [8].

Several results came back null or unclear. The difference between caps and stems was significant in one study and not in another [3] [4], and the six-species study reported no quantitative cap and stem data at all [1]. The stage-of-maturity results are labeled preliminary by their own authors, and the flush comparison was qualitative [1]. The zapotecorum genome work found no genetic explanation for that species' high concentration [3]. The authors of the 2022 survey say that the effect of substrate nutrients, developmental stage and weather on tryptamine content has not yet been studied [5]. No systematic inter-laboratory comparison of the same material was found. One 2024 study of five P. cubensis strains reports that a subset of its samples was also run at an independent laboratory with comparable results, but only its abstract could be read, and no figure from it is used here [39]. None of the peyote, iboga or toad papers read here measured how growing conditions change alkaloid content, so for those organisms the cultivation question has no direct data.

What is not known

The central open question is where strain differences come from. The data above are compatible with several explanations, and no study found for this page has measured gene expression, gene copy number and chemistry together in the same strains. Identity is a related gap. Since no comprehensive genetic reference exists for commercial strains [2], a strain name does not by itself fix what was studied.

It is also unclear how much of the variation between fruit bodies is biology and how much is sampling, since even "identical conditions" hide position in the chamber, flush number, moisture history and the exact moment of harvest, and few papers report them. As far as these searches could tell, only one study has varied conditions one at a time while measuring chemistry [6]. Whether yield and content trade against each other is not verified here, and whether any such trade-off holds in other strains is unknown.

Whether cultivated peyote or iboga matches the chemistry of wild plants is an open comparison, as is whether a cell line reproduces what a living toad's secretion contains [24]. Whether the mixture of compounds in an intact organism changes anything for healthy adults is untested, and no cultivation study can answer it.

What Metanoia asks

The questions Metanoia is set up to ask in this discipline are these. Which growing variables move the chemistry most when the others are held constant? Are differences between strains mainly a matter of gene regulation and environment rather than of the gene sequences themselves? Can a documented chain from strain to shelf make natural material reproducible enough for research?

Metanoia's long-term goal is a comprehensive research center: an institution that keeps monitoring and reporting the field's evidence, convenes researchers, registries and regulators around shared reporting standards, and also conducts its own research, beginning with a validated measure of flourishing and a naturalistic observational cohort studied under those standards, and growing toward laboratory work in cultivation, chemistry and genetics under full legal authorization. The center is planned, not built, and its location has not been decided. Metanoia does not hold or supply any material, and any laboratory work with controlled compounds would take place only under the legal authorization the law requires.

How it connects to the twelve dimensions

Cultivation sits underneath the dimensions. Two studies of the same kind of organism that did not record how it was grown may be studying different things, and then a finding about Perception or Nature Connectedness in one cannot be compared with a finding in the other.

History in brief

In 1958, Albert Hofmann and colleagues published a paper describing psilocybin as a psychotropic agent of the Mexican mushroom Psilocybe mexicana [27]. A guide to growing Psilocybe cubensis at home appeared in 1976 under the pen names O. T. Oss and O. N. Oeric, with a later attribution to Terence and Dennis McKenna that is not verified here [28]. For research, the lasting consequence is that the commercial cultivars studied carry the marks of clandestine domestication [9] and that strain names come largely from enthusiast communities and not from reference collections [8]. The 1976 item is graded 3.

The book on all twelve dimensions   Back to the twelve dimensions